Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

This study examines the prognostic significance of early molecular response using an expanded dataset in chronic myeloid leukemia patients enrolled in the International Randomized Study of Interferon and STI571 (IRIS). Serial molecular studies demonstrate decreases in BCR-ABL transcripts over time....

Full description

Saved in:
Bibliographic Details
Main Authors: Hughes, Timothy P. (Author) , Hochhaus, Andreas (Author) , Branford, Susan (Author) , Müller, Martin Christian (Author) , Kaeda, Jaspal S. (Author) , Foroni, Letizia (Author) , Druker, Brian J. (Author) , Guilhot, François (Author) , Larson, Richard A. (Author) , O'Brien, Stephen G. (Author) , Rudoltz, Marc S. (Author) , Mone, Manisha (Author) , Wehrle, Elisabeth (Author) , Modur, Vijay (Author) , Goldman, John M. (Author) , Radich, Jerald P. (Author)
Format: Article (Journal)
Language:English
Published: November 11, 2010
In: Blood
Year: 2010, Volume: 116, Issue: 19, Pages: 3758-3765
ISSN:1528-0020
DOI:10.1182/blood-2010-03-273979
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood-2010-03-273979
Get full text
Author Notes:Timothy P. Hughes, Andreas Hochhaus, Susan Branford, Martin C. Müller, Jaspal S. Kaeda, Letizia Foroni, Brian J. Druker, François Guilhot, Richard A. Larson, Stephen G. O'Brien, Marc S. Rudoltz, Manisha Mone, Elisabeth Wehrle, Vijay Modur, John M. Goldman, Jerald P. Radich, on behalf of the IRIS investigators

MARC

LEADER 00000caa a2200000 c 4500
001 1847161545
003 DE-627
005 20230710131649.0
007 cr uuu---uuuuu
008 230601s2010 xx |||||o 00| ||eng c
024 7 |a 10.1182/blood-2010-03-273979  |2 doi 
035 |a (DE-627)1847161545 
035 |a (DE-599)KXP1847161545 
035 |a (OCoLC)1389794108 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Hughes, Timothy P.  |e VerfasserIn  |0 (DE-588)1028643306  |0 (DE-627)731444167  |0 (DE-576)376158484  |4 aut 
245 1 0 |a Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia  |b an analysis from the International Randomized Study of Interferon and STI571 (IRIS)  |c Timothy P. Hughes, Andreas Hochhaus, Susan Branford, Martin C. Müller, Jaspal S. Kaeda, Letizia Foroni, Brian J. Druker, François Guilhot, Richard A. Larson, Stephen G. O'Brien, Marc S. Rudoltz, Manisha Mone, Elisabeth Wehrle, Vijay Modur, John M. Goldman, Jerald P. Radich, on behalf of the IRIS investigators 
264 1 |c November 11, 2010 
300 |b Diagramme 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 01.06.2023 
520 |a This study examines the prognostic significance of early molecular response using an expanded dataset in chronic myeloid leukemia patients enrolled in the International Randomized Study of Interferon and STI571 (IRIS). Serial molecular studies demonstrate decreases in BCR-ABL transcripts over time. Analyses of event-free survival (EFS) and time to progression to accelerated phase/blast crisis (AP/BC) at 7 years were based on molecular responses using the international scale (IS) at 6-, 12-, and 18-month landmarks. Patients with BCR-ABL transcripts > 10% at 6 months and > 1% at 12 months had inferior EFS and higher rate of progression to AP/BC compared with all other molecular response groups. Conversely, patients who achieved major molecular response [MMR: BCR-ABL (IS) ≤ 0.1%] by 18 months enjoyed remarkably durable responses, with no progression to AP/BC and 95% EFS at 7 years. The probability of loss of complete cytogenetic response by 7 years was only 3% for patients in MMR at 18 months versus 26% for patients with complete cytogenetic response but not MMR (P < .001). This study shows a strong association between the degree to which BCR-ABL transcript numbers are reduced by therapy and long-term clinical outcome, supporting the use of time-dependent molecular measures to determine optimal response to therapy. This study is registered at www.clinicaltrials.gov as NCT00006343. 
700 1 |a Hochhaus, Andreas  |e VerfasserIn  |4 aut 
700 1 |a Branford, Susan  |e VerfasserIn  |4 aut 
700 1 |a Müller, Martin Christian  |d 1972-  |e VerfasserIn  |0 (DE-588)121360296  |0 (DE-627)705409236  |0 (DE-576)181482819  |4 aut 
700 1 |a Kaeda, Jaspal S.  |e VerfasserIn  |4 aut 
700 1 |a Foroni, Letizia  |e VerfasserIn  |4 aut 
700 1 |a Druker, Brian J.  |e VerfasserIn  |4 aut 
700 1 |a Guilhot, François  |e VerfasserIn  |4 aut 
700 1 |a Larson, Richard A.  |e VerfasserIn  |4 aut 
700 1 |a O'Brien, Stephen G.  |e VerfasserIn  |4 aut 
700 1 |a Rudoltz, Marc S.  |e VerfasserIn  |4 aut 
700 1 |a Mone, Manisha  |e VerfasserIn  |4 aut 
700 1 |a Wehrle, Elisabeth  |e VerfasserIn  |4 aut 
700 1 |a Modur, Vijay  |e VerfasserIn  |4 aut 
700 1 |a Goldman, John M.  |e VerfasserIn  |4 aut 
700 1 |a Radich, Jerald P.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Blood  |d Washington, DC : American Society of Hematology, 1946  |g 116(2010), 19 vom: Nov., Seite 3758-3765  |h Online-Ressource  |w (DE-627)266886647  |w (DE-600)1468538-3  |w (DE-576)075961938  |x 1528-0020  |7 nnas  |a Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia an analysis from the International Randomized Study of Interferon and STI571 (IRIS) 
773 1 8 |g volume:116  |g year:2010  |g number:19  |g month:11  |g pages:3758-3765  |g extent:8  |a Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia an analysis from the International Randomized Study of Interferon and STI571 (IRIS) 
856 4 0 |u https://doi.org/10.1182/blood-2010-03-273979  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20230601 
993 |a Article 
994 |a 2010 
998 |g 121360296  |a Müller, Martin Christian  |m 121360296:Müller, Martin Christian  |d 60000  |d 61200  |e 60000PM121360296  |e 61200PM121360296  |k 0/60000/  |k 1/60000/61200/  |p 4 
999 |a KXP-PPN1847161545  |e 4328104802 
BIB |a Y 
SER |a journal 
JSO |a {"person":[{"family":"Hughes","given":"Timothy P.","display":"Hughes, Timothy P.","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Hochhaus","given":"Andreas","roleDisplay":"VerfasserIn","display":"Hochhaus, Andreas","role":"aut"},{"display":"Branford, Susan","roleDisplay":"VerfasserIn","role":"aut","family":"Branford","given":"Susan"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Müller, Martin Christian","given":"Martin Christian","family":"Müller"},{"given":"Jaspal S.","family":"Kaeda","role":"aut","roleDisplay":"VerfasserIn","display":"Kaeda, Jaspal S."},{"given":"Letizia","family":"Foroni","role":"aut","display":"Foroni, Letizia","roleDisplay":"VerfasserIn"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Druker, Brian J.","given":"Brian J.","family":"Druker"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Guilhot, François","given":"François","family":"Guilhot"},{"family":"Larson","given":"Richard A.","roleDisplay":"VerfasserIn","display":"Larson, Richard A.","role":"aut"},{"given":"Stephen G.","family":"O'Brien","role":"aut","display":"O'Brien, Stephen G.","roleDisplay":"VerfasserIn"},{"family":"Rudoltz","given":"Marc S.","roleDisplay":"VerfasserIn","display":"Rudoltz, Marc S.","role":"aut"},{"display":"Mone, Manisha","roleDisplay":"VerfasserIn","role":"aut","family":"Mone","given":"Manisha"},{"display":"Wehrle, Elisabeth","roleDisplay":"VerfasserIn","role":"aut","family":"Wehrle","given":"Elisabeth"},{"family":"Modur","given":"Vijay","display":"Modur, Vijay","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Goldman","given":"John M.","roleDisplay":"VerfasserIn","display":"Goldman, John M.","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Radich, Jerald P.","role":"aut","family":"Radich","given":"Jerald P."}],"title":[{"title_sort":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia","title":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia","subtitle":"an analysis from the International Randomized Study of Interferon and STI571 (IRIS)"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Gesehen am 01.06.2023"],"recId":"1847161545","language":["eng"],"name":{"displayForm":["Timothy P. Hughes, Andreas Hochhaus, Susan Branford, Martin C. Müller, Jaspal S. Kaeda, Letizia Foroni, Brian J. Druker, François Guilhot, Richard A. Larson, Stephen G. O'Brien, Marc S. Rudoltz, Manisha Mone, Elisabeth Wehrle, Vijay Modur, John M. Goldman, Jerald P. Radich, on behalf of the IRIS investigators"]},"origin":[{"dateIssuedKey":"2010","dateIssuedDisp":"November 11, 2010"}],"id":{"eki":["1847161545"],"doi":["10.1182/blood-2010-03-273979"]},"physDesc":[{"noteIll":"Diagramme","extent":"8 S."}],"relHost":[{"id":{"zdb":["1468538-3"],"eki":["266886647"],"issn":["1528-0020"]},"origin":[{"publisherPlace":"Washington, DC ; Philadelphia, Pa. ; Stanford, Calif.","dateIssuedDisp":"1946-","publisher":"American Society of Hematology ; Saunders ; HighWire Press","dateIssuedKey":"1946"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"journal of the American Society of Hematology","title":"Blood","title_sort":"Blood"}],"titleAlt":[{"title":"Blood online"}],"part":{"year":"2010","issue":"19","pages":"3758-3765","volume":"116","text":"116(2010), 19 vom: Nov., Seite 3758-3765","extent":"8"},"pubHistory":["1.1946 -"],"recId":"266886647","corporate":[{"display":"American Society of Hematology","roleDisplay":"Herausgebendes Organ","role":"isb"}],"language":["eng"],"note":["Gesehen am 21.04.2023"],"disp":"Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia an analysis from the International Randomized Study of Interferon and STI571 (IRIS)Blood","type":{"media":"Online-Ressource","bibl":"periodical"}}]} 
SRT |a HUGHESTIMOLONGTERMPR1120